Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FOLH1B

FOLH1B

Basics

Aliases:
This biomarker is also known as:
  • cell growth-inhibiting gene 26 protein,
  • PSMAL,
  • FOLHP,
  • Putative folate hydrolase 1B,
  • glutamate carboxypeptidase III,
  • GCPIII,
  • PSMA-LIKE,
  • folate hydrolase 1B,
  • Cell growth-inhibiting gene 26 protein,
  • folate hydrolase pseudogene,
  • N-acetylated-alpha-linked-acidic dipeptidase,
  • putative folate hydrolase 1B,
  • EC 3.4.-.-,
  • NAALADase,
  • FOLH2,
  • folate hydrolase 2,
  • PSM,
  • putative N-acetylated-alpha-linked acidic dipeptidase,
  • prostate-specific membrane antigen-like protein,
  • GCP3,
  • Q9HBA9,
  • Prostate-specific membrane antigen-like protein,

View in BioMuta

Description…

FOLH1B, or PSMAL, is a cytoplasmic protein. It has been found in the kidney and liver, and has not been detected in the prostate. GO annotations related to this gene include metallopeptidase activity and dipeptidase activity.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: FOLH1B

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: One
QA State: Under Review

Overview

No additional ovarian data available.

Performance Comment

FOLH1B (PSMAL) was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. FOLH1B (PSMAL) was not in the group of 13 selected for further validation.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.